Previous 10 | Next 10 |
FDA Review Cites DILIsym Results as Part of Turalio ® Submission DILIsym Services, Inc. , a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that sim...
There is a lot of truth to the adage that knowledge is power. This is especially true when it comes to developing new drugs — including a vaccine for the coronavirus, states Tony Sagami, editor of Weiss Ultimate Portfolio. For further details see: Simulation Plus- Adding Value to...
Pharmaceutical researchers can confirm much more than just their “gut instinct” with enhancements to all validated non-oral delivery route models Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pha...
Simulations Plus (SLP) through a joint proposal with the St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis, it has been awarded a new funded cooperative agreement from the USFDA.Both to establish novel in vitro/in silico models for the oral cavity route ...
Partnership will develop and validate unique in vitro/in silico models for oral cavity products Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods indust...
On receiving positive feedback on the first phase, Simulations Plus (SLP) has entered accelerated second phase of its collaboration with a large pharmaceutical company to modify its high-throughput pharmacokinetic ((HTPK)) simulation functionality within ADMET Predictorto support the sponsor ...
Improvements Establish HTPK Simulation Module as Key Gateway for Lead Compound Selection Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today...
Simulations Plus (SLP) entered into a collaborative research agreement with a large pharmaceutical company to evaluate the new AIDD Module in the recently launched version of ADMET Predictor.Pursuant to the agreement, the partner company has entrusted SLP with compound structure and activity ...
New AIDD Module applied to active therapeutic program to provide lead optimization support Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries,...
New artificial intelligence-driven drug design functionality offers scientists unrivaled methods for lead optimization Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods ...
News, Short Squeeze, Breakout and More Instantly...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...